(Q42234533)

19 October 2017

What are the pros and cons of the use of host-targeted agents against hepatitis C? (English)

1 reference

19 October 2017

Jean-Michel Pawlotsky

series ordinal

1

1 reference

19 October 2017

26 February 2014

1 reference

19 October 2017

1 reference

19 October 2017

105

1 reference

19 October 2017

22-25

1 reference

The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?

19 October 2017

1 reference

12 December 2020

Hepatitis C virus RNA replication

1 reference

12 December 2020

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

1 reference

12 December 2020

MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.

1 reference

12 December 2020

Cyclophilins as modulators of viral replication

1 reference

12 December 2020

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

12 December 2020

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors

1 reference

12 December 2020

MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis

1 reference

12 December 2020

Endoplasmic reticulum stress contributes to heart protection induced by cyclophilin D inhibition

1 reference

12 December 2020

Interferons and their use in persistent viral infections

1 reference

12 December 2020

Hepatitis C virus RNA translation

1 reference

12 December 2020

Treatment of chronic hepatitis C: current and future

1 reference

12 December 2020

What is the future of ribavirin therapy for hepatitis C?

1 reference

12 December 2020

Suppression of coronavirus replication by cyclophilin inhibitors

1 reference

12 December 2020

Hepatitis C virus entry

1 reference

12 December 2020

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

1 reference

12 December 2020

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

1 reference

12 December 2020

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

1 reference

12 December 2020

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

12 December 2020

Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis

1 reference

12 December 2020

Virion assembly and release

1 reference

12 December 2020

Treatment of HCV infection by targeting microRNA

1 reference

12 December 2020

The application and mechanism of action of ribavirin in therapy of hepatitis C.

1 reference

12 December 2020

Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients

1 reference

12 December 2020

10.1016/J.ANTIVIRAL.2014.02.008

Identifiers

DOI

1 reference

19 October 2017

0 references

1 reference

PubMed ID

24583032